MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. | MicrobiomeTrials
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-04-16Est. Completion: 2028-10-31
Enrollment target: 200 participants
Locations
Research site, Ancona, Italy
Research Site, Ancona, Italy
Research Site, Bergamo, Italy
Research site, Foggia, Italy
Research Site, Foggia, Italy
Research Site, Meldola, Italy
Research site, Milan, Italy
Research Site, Milan, Italy
Research site, Modena, Italy
Research Site, Modena, Italy
Research site, Naples, Italy
Research Site, Naples, Italy
Research Site, Padova, Italy
Research Site, Palermo, Italy
Research Site, Pisa, Italy
Research site, Pozzuoli, Italy
Research Site, Pozzuoli, Italy
Research Site, Roma, Italy
Research site, Rozzano, Italy
Research Site, Rozzano, Italy
Research site, Torino, Italy
Research Site, Torino, Italy
Research site, Verona, Italy
Other microbiome trials you might be interested in